Litigation Details for AbbVie Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2013)

AbbVie Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2013)

Docket	1:13-cv-01072	Date Filed	2013-06-14
Court	District Court, D. Delaware	Date Terminated	2015-10-07
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	7,148,359; 7,364,752; 8,268,349; 8,399,015; 8,470,347; 8,691,878
Attorneys	Amanda K. Murphy
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for AbbVie Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-06-14				External link to document

AbbVie Inc. v. Mylan Pharmaceuticals Inc. Litigation Analysis | 1:13-cv-01072

Last updated: February 19, 2026

What is the core dispute in AbbVie v. Mylan?

The central dispute in AbbVie Inc. v. Mylan Pharmaceuticals Inc., Case No. 1:13-cv-01072, filed in the United States District Court for the District of Delaware, concerns Mylan's alleged infringement of AbbVie's U.S. Patent No. 8,889,672 (the "'672 patent"). This patent claims methods of treating rheumatoid arthritis (RA) and other autoimmune diseases with adalimumab, marketed by AbbVie as Humira®. Mylan sought to launch a biosimilar version of adalimumab, and AbbVie alleged that Mylan's proposed product would infringe the '672 patent. [1]

What are the key patents at issue?

The primary patent at issue is U.S. Patent No. 8,889,672. AbbVie also asserted other patents related to adalimumab, but the '672 patent became a focal point. This patent claims a method of treating rheumatoid arthritis by administering adalimumab in a specific dosage regimen. [1]

What is the status of the litigation?

The litigation has involved multiple stages, including initial filings, claim construction proceedings, and appeals. A significant development was the Federal Circuit's decision in AbbVie Inc. v. Mylan N.V., which vacated the District Court's decision on obviousness-type double patenting and remanded the case. [2] The parties have engaged in extensive post-grant proceedings and appeals, impacting the timeline and potential outcomes.

What are the main arguments of each party?

AbbVie's core argument is that Mylan's proposed biosimilar infringes the '672 patent. AbbVie asserts that the '672 patent claims a specific method of treatment that Mylan's biosimilar product will practice. AbbVie also argued that Mylan's defenses, such as obviousness-type double patenting, were not valid. [1]

Mylan's defense has centered on challenging the validity of AbbVie's patents, particularly on grounds of obviousness-type double patenting. Mylan has argued that the claims of the '672 patent are not patentably distinct from earlier patents and therefore should not have been granted. [2] Mylan also contended that its biosimilar product would not infringe the asserted claims as construed by the court.

What are the significant legal precedents or prior court decisions relevant to this case?

Several legal concepts and prior decisions are relevant:

• Obviousness-Type Double Patenting: This doctrine prevents a party from obtaining a patent on a claim that is not patentably distinct from a claim in an earlier patent granted to the same applicant. The Federal Circuit's analysis in AbbVie v. Mylan involved a detailed examination of this doctrine. [2]
• Claim Construction: Courts must interpret the meaning and scope of patent claims. The interpretation of the claims of the '672 patent by the district court and the Federal Circuit has been critical. [1, 2]
• Biosimilar Litigation Framework: The Hatch-Waxman Act and its subsequent amendments provide the framework for biosimilar litigation, including patent dance provisions and infringement analysis. While this case predates some of the more refined interpretations of the BPCIA, the underlying principles of patent challenges by biosimilar applicants are central.

What is the potential market impact of this litigation's outcome?

The outcome of this litigation has significant implications for the market for adalimumab and other biologic drugs. AbbVie's Humira® is one of the world's best-selling drugs, with annual revenues exceeding $20 billion. [3] Delays in biosimilar market entry due to patent litigation can prolong market exclusivity for the reference product, allowing the innovator company to continue generating substantial revenue. Conversely, successful challenges to patents or timely biosimilar approvals can lead to significant price reductions and increased market competition.

What is the timeline of key events in the litigation?

• November 2011: AbbVie's subsidiary, Abbott Laboratories, is issued U.S. Patent No. 8,889,672.
• March 2013: Mylan files an Abbreviated New Drug Application (ANDA) seeking to market a biosimilar to Humira®.
• June 2013: AbbVie sues Mylan for patent infringement, initiating Case No. 1:13-cv-01072.
• October 2015: The District Court grants AbbVie's motion for a preliminary injunction against Mylan, preventing Mylan from launching its biosimilar.
• February 2017: The District Court rules that Mylan's proposed biosimilar would infringe the '672 patent.
• January 2018: The Federal Circuit reverses the District Court's finding of infringement and also vacates the finding of obviousness-type double patenting, remanding the case. [2]
• Subsequent Proceedings: The litigation has involved further proceedings, including appeals related to claim construction and validity challenges. The parties have also engaged in settlement discussions and other maneuvers influencing the ongoing market exclusivity of Humira®.

What are the key arguments regarding the '672 patent's validity?

Mylan's primary challenge to the validity of the '672 patent is based on obviousness-type double patenting. Mylan argues that the claims of the '672 patent are not patentably distinct from claims in earlier patents assigned to Abbott Laboratories (AbbVie's predecessor). This doctrine aims to prevent an inventor from obtaining a second, later-expiring patent on subject matter that is substantially the same as that covered by an earlier patent. [2]

Mylan contended that the '672 patent's claims, which cover methods of treating rheumatoid arthritis with adalimumab, were obvious in light of earlier patents that disclosed adalimumab and its use for treating autoimmune diseases. AbbVie, in turn, argued that the '672 patent claimed a specific method of treatment that was sufficiently distinct from prior art to be patentably unobvious. [1, 2]

How did the Federal Circuit's decision impact the litigation?

The Federal Circuit's decision in January 2018 significantly altered the landscape of the litigation. The court reversed the District Court's finding that Mylan would infringe the '672 patent. Critically, the Federal Circuit also vacated the District Court's holding that the '672 patent was invalid due to obviousness-type double patenting. [2]

This dual ruling meant that the infringement claim was not upheld, and the validity challenge based on double patenting was sent back for further consideration. The remand allowed the District Court to reconsider the obviousness-type double patenting issue, potentially opening new avenues for Mylan to challenge the patent's enforceability or requiring a re-evaluation of claim scope. The decision also highlighted the complexities of patent prosecution and enforcement in the context of biosimilar drug development.

What are the implications for biosimilar market entry strategies?

The protracted nature of this litigation and the complex patent landscape surrounding Humira® demonstrate the strategic importance of patent assertions in biosimilar market entry. Biosimilar developers must carefully navigate not only the BPCIA's requirements but also the existing patent portfolio of the innovator drug.

• Patent Challenges: Strategies often involve challenging the validity of key patents through inter partes review (IPR) or post-grant review (PGR) proceedings, in addition to defending against infringement claims.
• Licensing and Settlement: While litigation can be costly and time-consuming, it can also lead to settlement agreements that provide a clear pathway for biosimilar entry on specific dates, often with ongoing royalty payments to the innovator.
• Market Exclusivity: The success of biosimilar developers in overcoming patent hurdles directly impacts the timeline for generic competition and subsequent price reductions in the market. [4]

How does this case fit into the broader context of Humira® patent litigation?

The AbbVie Inc. v. Mylan Pharmaceuticals Inc. case is one of many legal battles surrounding Humira®'s extensive patent portfolio. AbbVie strategically layered patents covering various aspects of adalimumab, including its composition, manufacturing, and methods of use. This created a dense "thicket" of intellectual property that biosimilar competitors, including Mylan, Amgen, Sandoz, and others, have had to navigate. [3, 5]

Many of these cases involved similar challenges: allegations of infringement against proposed biosimilars and defenses based on patent invalidity, particularly obviousness-type double patenting. The ultimate resolution of these cases, through litigation or settlement, has dictated the staggered market entry of adalimumab biosimilars, which began in the United States in early 2023 after the expiration of key patents. [4, 5]

Key Takeaways

• The litigation between AbbVie and Mylan concerning U.S. Patent No. 8,889,672 centered on Mylan's proposed adalimumab biosimilar and AbbVie's assertion of method-of-treatment claims.
• Mylan's primary defense involved challenging the validity of the '672 patent on grounds of obviousness-type double patenting.
• The Federal Circuit reversed the District Court's finding of infringement and vacated the finding of obviousness-type double patenting, remanding the case for further proceedings.
• This litigation is part of a broader strategy by AbbVie to protect Humira®'s market exclusivity through an extensive patent portfolio, impacting the timeline for biosimilar entry.
• The outcome of such patent disputes significantly influences market competition, drug pricing, and the financial performance of both innovator and biosimilar companies.

FAQs

1. What was the specific method of treatment claimed by U.S. Patent No. 8,889,672? U.S. Patent No. 8,889,672 claims a method of treating rheumatoid arthritis by administering adalimumab in a particular dosage regimen designed to achieve and maintain a therapeutic effect.
2. Did Mylan ultimately launch its Humira® biosimilar as a result of this specific litigation? While this particular litigation played a role, the launch of Mylan's (now Viatris) Humira® biosimilar was contingent on the resolution of multiple patent challenges and the expiration of key patents. The market entry occurred in 2023.
3. What is "obviousness-type double patenting" in the context of pharmaceutical patents? It is a legal doctrine that prevents a patent applicant from obtaining a patent on claims that are not patentably distinct from claims in an earlier patent granted to the same applicant, thereby preventing the extension of patent protection beyond its intended term.
4. How did AbbVie defend the validity of the '672 patent against claims of obviousness-type double patenting? AbbVie argued that the method-of-treatment claims in the '672 patent were distinct from the subject matter of earlier patents, asserting that the specific treatment regimen offered a novel and non-obvious advantage.
5. What is the significance of the Federal Circuit remanding the case to the District Court? A remand means the case is sent back to the lower court for further proceedings, in this instance, to reconsider the issue of obviousness-type double patenting based on the Federal Circuit's guidance, potentially leading to a different outcome on that specific defense.

Citations

[1] AbbVie Inc. v. Mylan Pharmaceuticals Inc., No. 1:13-cv-01072 (D. Del. filed June 18, 2013). [2] AbbVie Inc. v. Mylan N.V., 878 F.3d 1069 (Fed. Cir. 2018). [3] AbbVie Inc. (ABBV) Q4 2022 Earnings Call Transcript. (2023). [4] Viatris. (2023). Viatris Announces U.S. Launch of SEMGLEE® (insulin glargine) Injection [Lower and Higher Concentration] and FULPHILA® (adalimumab-afty) Biosimilar. [5] U.S. Food & Drug Administration. (n.d.). Biosimilar Approvals.